Canada-based CRO Biopharma Services passes WHO inspection

By Maggie Lynch

- Last updated on GMT

(Image: Getty/IvinRadkov)
(Image: Getty/IvinRadkov)

Related tags WHO CRO assessment compliance Inspection Fda Ema bioequivalence Research Clinical trial

WHO recently assessed Biopharma Services, which demonstrated compliance across multiple regulatory and organizational guidelines – opening the doors to conduct more work with the WHO foundations.

Following the assessment, Biopharma Services, a Phase I/IIa and bioequivalence contract research organization (CRO), received a status of compliance from the World Health Organization (WHO) valid through January 1, 2021.

This status was received after the assessment by WHO demonstrated that Biopharma’s site met the guidelines of current good laboratory practices (cGLP), good clinical practice (GCP), as well as the European Medicines Agency regulations (EMA), Medicines and Healthcare Regulatory Association (MHR) guidelines, and International Standardization Organization (ISO) processes.

The assessment included the review of two clinical studies found to be in compliance with regulatory guidelines required by the World Health Organization’s (WHOs) for in vivo ​bioequvialance studies. The studies were conducted at the company’s Toronto, Canada site.

Renzo DiCarlo, CEO of Biopharma Services told us that the status of compliance “will also open the door for us [the company] to work with many WHO foundations.”

According to Biopharma, the assessment is one of first steps in the prequalification process when submitting a finished pharmaceutical product as an expression of interest for product evaluation (EOI). EOIs are issued by WHO following the consultation of the organization’s disease programs and clinical specialists.

Previous to this assessment, the Canada-based company completed three FDA inspections​ in 2017 with zero observations. The company previously stated that it received no Form 483’s or observations after its FDA inspection in 2015 either.

The company has an additional site in Columbia, Missouri as well as affiliate relationships with Brazil, China, and the eastern European region. 

Related news

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more